Minirin (Desmopressin Acetate)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers the insertion of aquaporin‑2 channels, allowing more water to be reabsorbed and reducing urine output.

The dose of Minirin is individualized by the prescribing clinician based on the patient’s condition, age, renal function and response. Dosage instructions are provided on the prescription label and should not be altered without medical guidance.

Safety data for desmopressin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The main alternative to desmopressin is natural vasopressin (synthetic ADH). Desmopressin has a longer half‑life, greater selectivity for V2 receptors, and minimal vasoconstrictive activity, making it preferred for chronic management of diabetes insipidus and nocturnal enuresis.

Minirin nasal spray should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and discard any product that appears discoloured or contaminated.

Minirin is supplied as a metered‑dose nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing normally. The other nostril may be used for subsequent doses if required.

The most critical safety concerns are severe hyponatraemia, water intoxication, and resultant neurological complications such as seizures or coma. Patients should be monitored for sudden changes in weight, headache, nausea, or confusion, and fluid intake may need to be restricted.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin, uncontrolled hyponatraemia, or conditions predisposing to water retention such as severe renal impairment. Caution is also advised for patients with a history of hyponatraemia or those taking interacting medications.